

# Stimulation of Humoral and Cellular Antibody Formation in Mice by Poly I<sub>r</sub>:C<sub>r</sub><sup>1</sup> (34469)

WILLIE TURNER, SUE P. CHAN, AND MICHAEL A. CHIRIGOS

National Cancer Institute, and Microbiological Associates, Inc., Bethesda, Maryland 20014

The synthetic double-stranded RNA, poly-riboinosinic-polyribocytidylic acid (poly I<sub>r</sub>:C<sub>r</sub>), has been shown to be a potent inducer of interferon (1). Animals treated with poly I<sub>r</sub>:C<sub>r</sub> have been shown to exhibit high levels of circulating interferon and thus were shown to be protected against the lethal effects of several non-oncogenic and oncogenic viruses (1, 2). Poly I<sub>r</sub>:C<sub>r</sub> has also been reported to induce antitumor activity in mice against several viral and nonviral induced transplantable tumors (3, 4). The mechanism by which poly I<sub>r</sub>:C<sub>r</sub> induces antitumor activity in mice is not known, but is not thought to be attributable solely, if at all, to interferon (3).

Braun and Nakano reported that complexes of polyadenylic-polyuridylic acid (poly A:U), enhanced the early rate of increase in number of antibody-forming spleen cells in mice immunized with sheep erythrocytes (5). This observation clearly establishes the adjuvant activity of poly A:U in mice. This report concerns the ability of poly I<sub>r</sub>:C<sub>r</sub> to induce a state of immunological hyperresponsiveness in mice.

**Materials and Methods. Mice.** Adult C<sub>57</sub>Bl/6 male and female mice, 6–10 weeks old, between 20–25 g, were obtained from the animal production section of the National Institutes of Health. Although this is an isogenic strain, the female of this strain rejects an isograft from male donors. This rejection is thought to be due to a histocompatible antigen (H-Y transplantation antigen) present in male skin which is determined by a locus on the y chromosome (6). Mice of

the same age were employed for antibody production and isograft studies.

**Grafting technique.** The grafting technique employed in this study is essentially the same as that employed by Howard *et al.* (7). Briefly, tail skin grafts from C<sub>57</sub>Bl/6 male mice were placed on the thoracic wall of female C<sub>57</sub>Bl/6 mice and covered with Vaseline-impregnated gauze and a plastic cast. Casts were removed 7 days after grafting and the grafts were inspected daily for signs of rejection. Grafts were considered to be rejected at the first signs of hemorrhage or induration.

**Poly I<sub>r</sub>:C<sub>r</sub>.** Polyriboinosinic-polyribocytidylic acid was purchased from Grand Island Biological Company (Gibco), Grand Island, New York. A stock concentration of poly I<sub>r</sub>:C<sub>r</sub> containing 10 mg/ml was stored at 4° and diluted in phosphate buffered saline (PBS), pH 6.0, to obtain the desired concentration of poly I<sub>r</sub>:C<sub>r</sub> to be used in the experiments.

**Antigen.** Sheep red blood cells (S-RBC) obtained commercially from Microbiological Associates, Inc., Bethesda, Md., were washed three times in 0.85% NaCl, resuspended in saline, and standardized photometrically to a concentration of  $5 \times 10^8$  cells/ml. Mice were immunized by intraperitoneal inoculation of  $10^8$  sheep cells in a 0.2-ml volume.

**Hemolytic antibody titration.** Mice were bled at various intervals following immunization with S-RBC. Individual serum samples were obtained from 5 to 8 mice/time interval, heat inactivated at 56° for 30 min and stored at -20° until titrated. The titer of hemolytic antibody in each serum sample was obtained by modification of the method described by Taliaferro and Taliaferro (8). Briefly, serial twofold dilutions of serum, 1:25 through

<sup>1</sup> This investigation was supported, in part, by NCI Public Health Service, Contract PH-43-66-887, at Microbiological Associates, Inc., Bethesda, Maryland.

1:1600, in 0.5-ml volumes were made in Veronal buffered saline (pH 7.3-7.4). An equal volume of 2% S-RBC was added to antiserum dilutions and allowed to stand at room temperature for 15 min for sensitization. Six-tenths ml of sensitized S-RBC was added to tubes containing 5C'<sub>50</sub>H units of guinea pig complement in 0.3-ml volume and 0.6 ml of Veronal buffered saline (VBS). Tubes were shaken and incubated at 37° for 30 min. Five-tenths ml of VBS was added to each tube and tubes were then centrifuged at 1000g for 10 min. Photometric reading of each tube at a wavelength of 500 mμ were taken on a Coleman Jr. photometer and compared to the photometric reading of a 100% hemolysis blank to determine the percentage hemolysis. Percentage hemolysis vs. dilution of serum were plotted on probit graph paper to determine the titer of hemolytic antibody. The hemolytic antibody titer is expressed at the number of 50% hemolytic units (H<sub>50</sub>)/ml of serum. The peak titer of hemolytic antibody consistently occurred 7 days after immunization with S-RBC.

*Statistical methods.* The *p* values were obtained by comparing each treatment group with control group by the *t* test (9) and Wilcoxon-Mann-Whitney test (10). The confidence intervals for the median were obtained by a method described by Dixon and Massey (11).

*Results.* Sheep red blood cell hemolytic antibody formation in mice treated with poly I<sub>r</sub>:C<sub>r</sub>. Mice were inoculated intraperitoneally with a dose of 200 μg of poly I<sub>r</sub>:C<sub>r</sub> at different time intervals before and after S-RBC immunization. Data in Fig. 1 show that 7 days after immunization all the regimens of poly I<sub>r</sub>:C<sub>r</sub> treatments employed resulted in the formation of increased titers of S-RBC hemolytic antibodies over S-RBC controls. The most significant enhancement of hemolytic antibody titer (3.1-fold) over controls occurred in mice simultaneously inoculated with poly I<sub>r</sub>:C<sub>r</sub> and S-RBC. The increased titers which occurred at 7 days were not reflected in any marked earlier appearance of higher titer of antibodies, nor were the titers maintained significantly higher at 15 days.

TABLE I. The Effect of Treatment of Mice with Various Doses of Poly I<sub>r</sub>:C<sub>r</sub> on Hemolytic Antibody Formation.

Treatment		Hemolytic antibody <sup>c</sup> titer (H <sub>50</sub> /ml)	<i>p</i> <sup>d</sup>
Dose of poly I <sub>r</sub> :C <sub>r</sub> (μg/mouse) <sup>a</sup>	Antigen <sup>b</sup>		
1	S-RBC	386	>0.10
10	S-RBC	592	<0.01
50	S-RBC	507	<0.05
100	S-RBC	787	<0.001
200	S-RBC	728	<0.001
—	S-RBC	292	—

<sup>a</sup> Poly I<sub>r</sub>:C<sub>r</sub> was inoculated intraperitoneally in 0.2-ml volume at time of S-RBC immunization (D<sub>0</sub>).

<sup>b</sup> Mice were inoculated intraperitoneally with 10<sup>8</sup> S-RBC on D<sub>0</sub> and bled 7 days after immunization.

<sup>c</sup> Hemolytic antibody titer represents mean of hemolytic antibody titer of 5 mice. Standard error of the mean is 73.3 units, with 24 *df*.

<sup>d</sup> The *p* values were obtained by a *t* test.

*Effect of treatment of mice with different doses of poly I<sub>r</sub>:C<sub>r</sub> on hemolytic antibody formation to S-RBC.* Since simultaneous injection of poly I<sub>r</sub>:C<sub>r</sub> resulted in the formation of the highest titer of hemolytic antibody, this treatment schedule was employed to ascertain the lowest concentration of poly I<sub>r</sub>:C<sub>r</sub> which would enhance hemolytic antibody formation. Results in Table I show that treatment of mice with 100 μg of poly I<sub>r</sub>:C<sub>r</sub> resulted in a maximum increase in titer of hemolytic antibodies over S-RBC controls (approximately 3-fold). Treatment of mice with 200 μg of poly I<sub>r</sub>:C<sub>r</sub> did not result in additional enhancement of hemolytic antibody titer beyond that induced in mice treated with 100 μg of poly I<sub>r</sub>:C<sub>r</sub>. The results obtained in mice injected with 10 or 50 μg of poly I<sub>r</sub>:C<sub>r</sub> indicated that enhancement of hemolytic antibody formation occurred, which would represent a response to dose of poly I<sub>r</sub>:C<sub>r</sub>. The increase in hemolytic antibody attained in mice injected with 1 μg of poly I<sub>r</sub>:C<sub>r</sub> was not considered significantly greater (*p* > 0.10) than that observed in control mice. The results of this study show that the minimum dose of poly I<sub>r</sub>:C<sub>r</sub> which will enhance hemolytic antibody titers signifi-

cantly higher than control values is 10  $\mu$ g.

In subsequent studies single-stranded RNA, poly I<sub>r</sub>, or poly C were tested for possible enhancing effects. Injection of 200  $\mu$ g of either polynucleotide alone did not enhance hemolytic antibody formation in mice immunized with S-RBC. The findings suggest that only the complexed polynucleotides exhibit adjuvant activity in mice.

*The effects of poly I<sub>r</sub>:C<sub>r</sub> on isograft survival.* Female C<sub>57</sub>B1/6 mice treated at different time intervals with 200  $\mu$ g of poly I<sub>r</sub>:C<sub>r</sub> received grafts of tail skin from C<sub>57</sub>B1/6 male mice. Results in Table II show that the median survival time (MST) of control

grafts was 23 days. Earlier rejection of skin grafts occurred in mice which received treatment with poly I<sub>r</sub>:C<sub>r</sub>. Mice which were grafted and received one treatment with poly I<sub>r</sub>:C<sub>r</sub> (200  $\mu$ g) on the same day rejected their grafts 13 days prior to controls. A similar response was attained in mice which received poly I<sub>r</sub>:C<sub>r</sub> 10 days prior to and again on the day of grafting, and in mice which received 5 treatments (D<sub>-3</sub>, D<sub>-1</sub>, D<sub>0</sub>, D<sub>+2</sub>, D<sub>+7</sub>). The earlier time of skin graft rejection in these treated groups was highly significant ( $p < 0.005$ ). The group of mice which were injected with poly I<sub>r</sub>:C<sub>r</sub> 10 days prior to receiving skin grafts rejected their grafts at a MST




FIG. 1. Hemolytic antibody formation in poly I<sub>r</sub>:C<sub>r</sub>-treated mice immunized with sheep erythrocytes. D<sub>0</sub> = day of sheep erythrocyte inoculation.

TABLE II. The Effect of Poly I<sub>r</sub>:C<sub>r</sub> Treatment of Female C<sub>57</sub>Bl/6 Mice on the Survival Time of Isografts from Male C<sub>57</sub>Bl/6 Donor.

Poly I <sub>r</sub> :C <sub>r</sub> <sup>a</sup> treatment schedule	No. of mice with graft	MST <sup>b</sup> of graft (days)	95% confidence inter- val for MST of graft	<i>p</i> <sup>c</sup>
D <sub>-10</sub>	14	24	20 ≤ MST ≤ 26	> 0.10
D <sub>0</sub>	9	10	10 ≤ MST ≤ 17	< 0.005
D <sub>-10</sub> , D <sub>0</sub>	7	10	8 ≤ MST ≤ 21	< 0.005
D <sub>-3</sub> , D <sub>-1</sub> , D <sub>0</sub> , D <sub>+2</sub> , D <sub>+1</sub>	7	10	8 ≤ MST ≤ 16	< 0.005
None	10	23	18 ≤ MST ≤ 34	—

<sup>a</sup> Mice inoculated intraperitoneally with 200 μg of poly I<sub>r</sub>:C<sub>r</sub> on each day of treatment. D<sub>0</sub> = day of grafting, while D<sub>-10</sub> = 10 days before grafting.

<sup>b</sup> MST = median survival time.

<sup>c</sup> The Wilcoxon-Mann-Whitney test was employed to obtain *p* values.

similar to nontreated controls. The excellent effects achieved with the treatment of poly I<sub>r</sub>:C<sub>r</sub>, at the time of grafting, indicates that one treatment was sufficient to enhance graft rejection.

*Discussion.* The results reported herein demonstrate the adjuvant activities of poly I<sub>r</sub>:C<sub>r</sub> in mice. These findings confirm the observation of Braun and Nakano that double stranded polynucleotides stimulate antibody formation in mice to sheep erythrocytes (5). In addition, our results show that poly I<sub>r</sub>:C<sub>r</sub> treatment significantly reduced the survival time of isografts in mice. Thus, the enhanced immunological responsiveness induced by poly I<sub>r</sub>:C<sub>r</sub> to two antigens, S-RBC and H-Y transplantation antigen (isografts), show that this polynucleotide copolymer is capable of stimulating both humoral and cellular antibody formation.

The responses achieved, when the time of injection and the dose of poly I<sub>r</sub>:C<sub>r</sub> was varied, were of interest. Simultaneous administration of poly I<sub>r</sub>:C<sub>r</sub> and antigen resulted in maximum increase in antibody formation. A single dose was sufficient for this stimulation. A concentration of poly I<sub>r</sub>:C<sub>r</sub> as low as 10 μg was sufficient to significantly enhance antibody formation to S-RBC. Of particular interest were the results achieved with skin isografts. The very early rejection of the grafts (10 days) indicate that a very strong cellular immunity was established in grafted mice treated with one dose of poly I<sub>r</sub>:C<sub>r</sub>.

The mechanism(s) by which poly I<sub>r</sub>:C<sub>r</sub> protects mice against viral and nonviral in-

duced transplantable tumors is, as yet, not clearly defined. The ability of poly I<sub>r</sub>:C<sub>r</sub> to stimulate antibody formation must also be considered as an important factor in the mechanism(s) by which poly I<sub>r</sub>:C<sub>r</sub> exerts its antitumor effects.

*Summary.* Polyribonucleosinic-polyribocytidilic acid stimulated formation of hemolytic antibodies in mice immunized with sheep erythrocytes. Similarly, poly I<sub>r</sub>:C<sub>r</sub> treatment of mice resulted in a marked reduction in survival of isografts. Temporarily, administration of poly I<sub>r</sub>:C<sub>r</sub> at the time of exposure of mice to antigen resulted in optimal enhancement of humoral and cellular antibody formation. Optimal enhancement of both humoral and cellular antibody formation was induced by 100–200 μg of poly I<sub>r</sub>:C<sub>r</sub>, while significant stimulation of hemolytic antibody formation was induced by a lower dose of 10 μg of poly I<sub>r</sub>:C<sub>r</sub>.

We wish to thank Mr. Hugh Pettigrew of the Biometry Branch, National Cancer Institute, for the statistical evaluation of the experimental data.

1. Field, A. K., Tytell, A. A., Sampson, G. P., and Hilleman, M. R., Proc. Natl. Acad. Sci. U. S. 58, 1004 (1967).

2. Sarma, P. S., Shin, G., Neubauer, R. H., Baron, S., and Huebner, R. J., Proc. Natl. Acad. Sci. U. S. 62, 1046 (1969).

3. Levy, H. B., Law, L. W., and Rabson, A. S., Proc. Natl. Acad. Sci. U. S. 62, 357 (1969).

4. Zelenick, L. D. and Bhuyan, B. K., Proc. Soc. Exptl. Biol. Med. 130, 126 (1969).

5. Braun, W. and Nakano, M., Science 157, 819 (1967).

6. Silvers, W. K., Billingham, R. E., and Sandford, B. H., *Nature* **220**, 401 (1968).
7. Howard, R. J., Dougherty, S. F., and Mergenhagen, S. E., *J. Immunol.* **101**, 301 (1968).
8. Taliaferro, W. H. and Taliaferro, L. G., *J. Infect Diseases* **87**, 37 (1950).
9. Campbell, R. C., *in* "Statistics for Biologists." p. 186. Cambridge Univ. Press, London/New York (1967).
10. Snedecar, G. W. and Cochran, W. G., *in* "Statistical Methods," 6th ed., pp. 130-131. Iowa State Univ. Press, Ames (1967).
11. Dixon, W. J. and Massey, F. J., *in* "Introduction to Statistical Analysis," 2nd ed., p. 294. McGraw-Hill, New York (1957).

---

Received Sept. 8, 1969. P.S.E.B.M., 1970, Vol. 133.